Trial population
angina, TED, CHF, TAO, depression
MYOCARDIAL INFARCTION, STD, CONGESTIVE HEART FAILURE, CHF, HEART, TAO
From November 2019 to January 2021, a total of 935 patients were screened and 86 patients were equally and randomly allocated to either empagliflozin or the placebo group. During the time of the study, 11 individuals (empagliflozin group: 6, placebo group: 5) were lost to follow‐up, and eventually, a total of 75 patients were included in the analyses. A detailed explanation of screening, randomization, and follow‐up is shown in Figure Comparison of baseline characteristics between treatment groups.
Abbreviations: ACE, angiotensin‐converting enzyme; AF, angina frequency; ARB, angiotensin II receptor blockers; AS, angina stability; BB, beta blocker; BMI, body mass index; CABG, coronary artery bypass grafting; CCB, calcium channel blocker; CHF, congestive heart failure; HRR, heart rate recovery; MI, myocardial infarction; NYHA: New York Heart Association; PCI, percutaneous coronary intervention; PL, physical limitation; PPI, proton pump inhibitor; QOL, quality of life; STD, ST depression; TAO, time to angina onset; TED, treadmill exercise duration; TS, treatment satisfaction.Obtained from independent sample Obtained from Obtained from Mann–Whitney Obtained from Fisher exact test using Monte Carlo simulations.